Leslie Williams, hC Bioscience CEO

With a new start­up, ARCH and Take­da wade in­to grow­ing search for a Swiss Army knife RNA drug

ARCH and Take­da are step­ping — if not quite leap­ing — in­to one of the hottest new ar­eas in RNA drug de­vel­op­ment: tR­NA.

On Wednes­day the promi­nent VC firm and the Japan­ese phar­ma, along with tech-ori­ent­ed 8VC, an­nounced a $24 mil­lion in­vest­ment in hC Bio­science, a new start­up that will try to use this once-over­looked cor­ner of ge­net­ic ma­chin­ery to de­vel­op treat­ments for rare dis­eases and can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.